Vincristine liposomal (Marqibo) in combination with chemotherapy for elderly patients with newly diagnosed CD20 positive diffuse large B-cell lymphoma – first line

Record ID 32016000412
Authors' objectives: Diffuse large B-cell lymphoma is a cancer of white blood cells called lymphocytes that normally help the body to fight infections. Lymphoma is more common among older people. Treating older patients who often have other additional medical conditions can be a difficult task. Many of the drugs currently used for the treatment of lymphoma can have serious side effects. Vincristine liposomal is a new form of a chemotherapy drug called vincristine that may be more effective and less toxic than current chemotherapy because it is encapsulated in a protective shell. It is delivered straight into the bloodstream via a drip. Some studies have suggested vincristine liposomal may be helpful for elderly people who have had no previous treatment for lymphoma and more studies are now aiming to show how well it works and whether it is safe to use. If vincristine liposomal is licenced for use in the UK, it could be a new treatment option for newly diagnosed elderly patients with diffuse large B-cell lymphoma. It may improve survival and quality of life as it may cause fewer side effects than current treatments.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Humans
  • Aged
  • Liposomes
  • Lymphoma, Large B-Cell, Diffuse
  • Phospholipids
  • Vincristine
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.